Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/44895 |
Resumo: | The present study aims to evaluate the effectiveness of pimavanserin in patients with psychosis in Parkinson's disease. Its effects on the clinical picture of psychosis were evaluated, as well as its adverse reactions and influences on patients' quality of life. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 8 articles. Articles were searched in PubMed databases, excluding simple literature reviews and incomplete articles. Those published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it is concluded that pimavanserin demonstrates effectiveness in reducing hallucinogenic and delusional symptoms. Furthermore, it was found that the combination of pimavanserin with other medications, especially clozapine, showed promise in terms of safety, especially in improving cognitive functions. Patients showed improvements in the quality of sleep and wakefulness, in addition to a significant reduction in symptoms. Furthermore, side effects include pneumonia, episodes of syncope, obstructive pulmonary disease, pulmonary embolism and deep vein thrombosis. It is expected that future studies will continue to develop more intervention research on the effectiveness of the medication in treating Parkinson's disease, highlighting benefits and improvements in patients' quality of life through the use of the drug in medical practice. |
id |
UNIFEI_d3428a560904de07864e14bc1763d007 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/44895 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemáticaEfficacy of pimavanserin for patients with psychosis in Parkinson's disease: A systematic reviewEficacia de pimavanserina para pacientes con psicosis en enfermedad de Parkinson: Una revisión sistemáticaParkinson's diseasePsychotic disordersAntipsychotic agents.Enfermedad de ParkinsonDesórdenes psicóticosAgentes antipsicóticos.Doença de ParkinsonTranstornos psicóticosAgentes antipsicóticos.The present study aims to evaluate the effectiveness of pimavanserin in patients with psychosis in Parkinson's disease. Its effects on the clinical picture of psychosis were evaluated, as well as its adverse reactions and influences on patients' quality of life. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 8 articles. Articles were searched in PubMed databases, excluding simple literature reviews and incomplete articles. Those published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it is concluded that pimavanserin demonstrates effectiveness in reducing hallucinogenic and delusional symptoms. Furthermore, it was found that the combination of pimavanserin with other medications, especially clozapine, showed promise in terms of safety, especially in improving cognitive functions. Patients showed improvements in the quality of sleep and wakefulness, in addition to a significant reduction in symptoms. Furthermore, side effects include pneumonia, episodes of syncope, obstructive pulmonary disease, pulmonary embolism and deep vein thrombosis. It is expected that future studies will continue to develop more intervention research on the effectiveness of the medication in treating Parkinson's disease, highlighting benefits and improvements in patients' quality of life through the use of the drug in medical practice.El presente estudio tiene como objetivo evaluar la eficacia de pimavanserina en pacientes con psicosis en la enfermedad de Parkinson. Se evaluaron sus efectos sobre el cuadro clínico de la psicosis, así como sus reacciones adversas e influencias en la calidad de vida de los pacientes. Se trata de una Revisión Sistemática de la Literatura de carácter cualitativo, con una estrategia de búsqueda de la evaluación metodológica Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) y Critical Appraisal Skill Program (CASP), analizando un total de 8 artículos. Se buscaron artículos en las bases de datos PubMed, excluyendo revisiones bibliográficas simples y artículos incompletos. Se incluyeron aquellos publicados en los últimos 10 años (2013-2023) y disponibles en inglés. Tras un análisis sistemático de los estudios, se concluye que la pimavanserina demuestra eficacia para reducir los síntomas alucinógenos y delirantes. Además, se descubrió que la combinación de pimavanserina con otros medicamentos, especialmente clozapina, era prometedora en términos de seguridad, especialmente en la mejora de las funciones cognitivas. Los pacientes mostraron mejoras en la calidad del sueño y la vigilia, además de una reducción significativa de los síntomas. Además, los efectos secundarios incluyen neumonía, episodios de síncope, enfermedad pulmonar obstructiva, embolia pulmonar y trombosis venosa profunda. Se espera que futuros estudios continúen desarrollando más investigaciones de intervención sobre la eficacia del medicamento en el tratamiento de la enfermedad de Parkinson, destacando los beneficios y mejoras en la calidad de vida de los pacientes mediante el uso del medicamento en la práctica médica.O presente estudo tem como objetivo avaliar a eficácia da pimavanserina em pacientes com psicose na doença de Parkinson. Foram avaliados seus efeitos no quadro clínico da psicose, assim como suas reações adversas e influências na qualidade de vida dos pacientes. Trata-se de uma Revisão Sistemática da Literatura de natureza qualitativa, com estratégia de busca os Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) e avaliação metodológica Critical Appraisal Skill Programme (CASP), analisando-se ao total 8 artigos. Os artigos foram pesquisados nas bases de dados PubMed, excluindo revisões simples de literatura e artigos incompletos. Foram incluídos os publicados nos últimos 10 anos (2013-2023) e disponibilizados em inglês. Após uma análise sistemática dos estudos, conclui-se que a pimavanserina demonstra eficácia na redução dos sintomas alucinógenos e delirantes. Além disso, constatou-se que a combinação da pimavanserina com outros medicamentos, especialmente a clozapina, se mostrou promissora em termos de segurança, principalmente na melhora das funções cognitivas. Os pacientes apresentaram melhorias na qualidade do sono e vigília, além de redução significativa dos sintomas. Ademais, entre os efeitos colaterais estão pneumonia, episódios de síncope, doença pulmonar obstrutiva, embolia pulmonar e trombose venosa profunda. Espera-se que estudos futuros continuem a desenvolver mais pesquisas de intervenção sobre a eficácia da medicação no tratamento da doença de Parkinson, destacando benefícios e melhorias na qualidade de vida dos pacientes através do uso do fármaco na prática médica.Research, Society and Development2024-01-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4489510.33448/rsd-v13i1.44895Research, Society and Development; Vol. 13 No. 1; e13713144895Research, Society and Development; Vol. 13 Núm. 1; e13713144895Research, Society and Development; v. 13 n. 1; e137131448952525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/44895/35856Copyright (c) 2024 Rayanne da Cunha Mendes; Sâmara Pesqueira Souza; Luis Claudio Almeida da Silva Junior; Jordy Silva de Carvalho; Victor Hugo Oliveira Martins Coelho ; Wagner Gonçalves Hortahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMendes, Rayanne da Cunha Souza, Sâmara Pesqueira Silva Junior, Luis Claudio Almeida da Carvalho, Jordy Silva de Coelho , Victor Hugo Oliveira Martins Horta, Wagner Gonçalves 2024-02-01T09:48:39Zoai:ojs.pkp.sfu.ca:article/44895Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-02-01T09:48:39Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática Efficacy of pimavanserin for patients with psychosis in Parkinson's disease: A systematic review Eficacia de pimavanserina para pacientes con psicosis en enfermedad de Parkinson: Una revisión sistemática |
title |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática |
spellingShingle |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática Mendes, Rayanne da Cunha Parkinson's disease Psychotic disorders Antipsychotic agents. Enfermedad de Parkinson Desórdenes psicóticos Agentes antipsicóticos. Doença de Parkinson Transtornos psicóticos Agentes antipsicóticos. |
title_short |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática |
title_full |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática |
title_fullStr |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática |
title_full_unstemmed |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática |
title_sort |
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática |
author |
Mendes, Rayanne da Cunha |
author_facet |
Mendes, Rayanne da Cunha Souza, Sâmara Pesqueira Silva Junior, Luis Claudio Almeida da Carvalho, Jordy Silva de Coelho , Victor Hugo Oliveira Martins Horta, Wagner Gonçalves |
author_role |
author |
author2 |
Souza, Sâmara Pesqueira Silva Junior, Luis Claudio Almeida da Carvalho, Jordy Silva de Coelho , Victor Hugo Oliveira Martins Horta, Wagner Gonçalves |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Mendes, Rayanne da Cunha Souza, Sâmara Pesqueira Silva Junior, Luis Claudio Almeida da Carvalho, Jordy Silva de Coelho , Victor Hugo Oliveira Martins Horta, Wagner Gonçalves |
dc.subject.por.fl_str_mv |
Parkinson's disease Psychotic disorders Antipsychotic agents. Enfermedad de Parkinson Desórdenes psicóticos Agentes antipsicóticos. Doença de Parkinson Transtornos psicóticos Agentes antipsicóticos. |
topic |
Parkinson's disease Psychotic disorders Antipsychotic agents. Enfermedad de Parkinson Desórdenes psicóticos Agentes antipsicóticos. Doença de Parkinson Transtornos psicóticos Agentes antipsicóticos. |
description |
The present study aims to evaluate the effectiveness of pimavanserin in patients with psychosis in Parkinson's disease. Its effects on the clinical picture of psychosis were evaluated, as well as its adverse reactions and influences on patients' quality of life. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 8 articles. Articles were searched in PubMed databases, excluding simple literature reviews and incomplete articles. Those published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it is concluded that pimavanserin demonstrates effectiveness in reducing hallucinogenic and delusional symptoms. Furthermore, it was found that the combination of pimavanserin with other medications, especially clozapine, showed promise in terms of safety, especially in improving cognitive functions. Patients showed improvements in the quality of sleep and wakefulness, in addition to a significant reduction in symptoms. Furthermore, side effects include pneumonia, episodes of syncope, obstructive pulmonary disease, pulmonary embolism and deep vein thrombosis. It is expected that future studies will continue to develop more intervention research on the effectiveness of the medication in treating Parkinson's disease, highlighting benefits and improvements in patients' quality of life through the use of the drug in medical practice. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-01-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/44895 10.33448/rsd-v13i1.44895 |
url |
https://rsdjournal.org/index.php/rsd/article/view/44895 |
identifier_str_mv |
10.33448/rsd-v13i1.44895 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/44895/35856 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 13 No. 1; e13713144895 Research, Society and Development; Vol. 13 Núm. 1; e13713144895 Research, Society and Development; v. 13 n. 1; e13713144895 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052637396336640 |